Baillie Gifford & Co’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Baillie Gifford & Co’s Portfolio ORTX Stock Details ORTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-274,000	Closed	-$11.3M	–	435
2020 Q3	$11.3M	Hold	274,000	–	–	0.01%	204
2020 Q2	$16.4M	Hold	274,000	–	–	0.01%	182
2020 Q1	$20.6M	Hold	274,000	–	–	0.02%	145
2019 Q4	$37.7M	Buy	274,000 +181,500	+196%	+$22.1M	0.04%	137
2019 Q3	$11M	Hold	92,500	–	–	0.01%	176
2019 Q2	$12.9M	Hold	92,500	–	–	0.01%	182
2019 Q1	$16.5M	Hold	92,500	–	–	0.02%	168
2018 Q4	$14.6M	Buy	+92,500	New	+$13.8M	0.02%	166

Other funds holding ORTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Baillie Gifford & Co's ORTX Position: Q4 2020 in Review

Baillie Gifford & Co sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q4 2020, closing a stake of 274,000 shares — an estimated $11.3M sold.

Baillie Gifford & Co first reported a position in ORTX in Q4 2018 and held it in 8 quarters. The position peaked at $37.7M in Q4 2019. 77 funds tracked by Wall St. Rank hold ORTX as of Q4 2020.

Baillie Gifford & Co reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q4 2020 after selling out during the quarter.
Baillie Gifford & Co sold 274,000 Orchard Therapeutics plc American Depositary Shares shares in Q4 2020, an estimated $11.3M.
Baillie Gifford & Co first reported a position in Orchard Therapeutics plc American Depositary Shares in Q4 2018 and held it in 8 quarters.
Baillie Gifford & Co's Orchard Therapeutics plc American Depositary Shares position peaked at $37.7M in Q4 2019.
77 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q4 2020.

Based on Baillie Gifford & Co's 13F filing for Q4 2020, filed 10 Feb 2021.